Internal Medicine, Medical Oncology · Orlando, FL
NPI
1467627653
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1400 S Orange Ave
Orlando, FL, 32806
Phone (877) 876-3627
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.2M
149,986 services
Medicare patients, 2024
386
Average age 71
Drug cost, 2024
$5.0M
1,592 prescriptions
Company payments, 2025
$112K
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Yuanbin Chen was code J9299 (injection, nivolumab, 1 mg), 47,805 times for 24 patients. In total Yuanbin Chen billed 149,986 services in 180 codes, and Medicare paid $4.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-08-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9299 Injection, nivolumab, 1 mg | Office | 47,805 | 24 | $24.61 | $1.2M |
| J9267 Injection, paclitaxel, 1 mg | Office | 6,978 | 17 | $0.08 | $534 |
| J9173 Injection, durvalumab, 10 mg | Office | 6,301 | 11 | $63.69 | $401K |
| J9228 Injection, ipilimumab, 1 mg | Office | 5,291 | 12 | $137.05 | $725K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 4,818 | 15 | $44.82 | $216K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 3,450 | 13 | $0.11 | $378 |
| J9304 Injection, pemetrexed (pemfexy), 10 mg | Office | 3,240 | 13 | $43.27 | $140K |
| J1930 Injection, lanreotide, 1 mg | Office | 2,400 | 12 | $38.42 | $92K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,216 | 73 | $0.09 | $199 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,230 | 38 | $0.71 | $876 |
| 36415 Venipuncture Blood Collection | Office | 862 | 145 | $8.65 | $7,456 |
| J9045 Injection, carboplatin, 50 mg | Office | 849 | 35 | $2.86 | $2,426 |
| 85025 Blood Count | Office | 843 | 134 | $7.61 | $6,416 |
| 80053 Clinical Chemistry | Office | 778 | 130 | $10.35 | $8,052 |
| 96413 Chemotherapy Administration | Office | 587 | 138 | $90.68 | $53K |
By year: 2022 $5.6M for 229,665 services; 2023 $4.5M for 158,130 services; 2024 $4.2M for 149,986 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 862 | 145 | $8.65 | $7,456 |
| 85025 Blood Count | 843 | 134 | $7.61 | $6,416 |
| 80053 Clinical Chemistry | 778 | 130 | $10.35 | $8,052 |
| 84443 Clinical Chemistry | 362 | 80 | $16.46 | $5,959 |
| 83735 Clinical Chemistry | 196 | 49 | $6.57 | $1,288 |
| 84439 Clinical Chemistry | 93 | 40 | $8.84 | $822 |
| 83615 Clinical Chemistry | 88 | 36 | $5.87 | $516 |
| 82024 Clinical Chemistry | 64 | 36 | $37.38 | $2,392 |
| 82533 Clinical Chemistry | 61 | 35 | $15.76 | $962 |
| 87340 Immunoassay | 54 | 41 | $10.12 | $546 |
Medicare prescription drug claims, 2024
In 2024, the drug Yuanbin Chen prescribed most often to Medicare patients was Prochlorperazine Maleate, with 198 prescriptions and refills. In total Yuanbin Chen wrote 1,592 Medicare prescriptions that cost $5.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prochlorperazine Maleate Generic | 198 | 198 | 123 | $2,960 |
| Tagrisso Osimertinib Mesylate | 132 | 132 | 16 | $2.4M |
| Prednisone Generic | 131 | 188 | 56 | $812 |
| Dexamethasone Generic | 119 | 139 | 73 | $1,680 |
| Levothyroxine Sodium Generic | 117 | 240 | 37 | $1,487 |
| Olanzapine Generic | 110 | 114 | 68 | $427 |
| Folic Acid Generic | 52 | 91 | 23 | $133 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 50 | 50 | 25 | $909 |
| Mektovi Binimetinib | 46 | 46 | Under 11 | $432K |
| Braftovi Encorafenib | 43 | 47 | Under 11 | $790K |
| Ondansetron Odt Ondansetron | 39 | 39 | 25 | $634 |
| Eliquis Apixaban | 37 | 51 | Under 11 | $29K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 36 | 36 | 30 | $377 |
| Omeprazole Generic | 35 | 67 | 17 | $355 |
| Neulasta Pegfilgrastim | 29 | 29 | 12 | $201K |
Brand drugs: 462 claims; generic drugs: 1,130 claims; opioid claims: 94.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Yuanbin Chen $112K ($112K in general payments such as food, travel and fees) from 31 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $47K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 37 | $47K |
| Amgen Inc. AMGN | 20 | $21K |
| Jazz Pharmaceuticals Inc. JAZZ | 13 | $18K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 11 | $12K |
| Pfizer Inc. PFE | 9 | $8,923 |
| E.R. Squibb & Sons, L.L.C. BMY | 21 | $2,341 |
| Merck Sharp & Dohme LLC MRK | 8 | $1,380 |
| Array Biopharma Inc PFE | 6 | $816 |
| Iovance Biotherapeutics, Inc. IOVA | 2 | $233 |
| Janssen Biotech, Inc. JNJ | 2 | $177 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.